Work

A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies

Year: 2021

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-020-04229-3

Authors: Katharine A. Collier, Hugo Valencia, Herbert Newton, Erinn M. Hade, Douglas W. Sborov, Robert Cavaliere, Ming Poi, Mitch A. Phelps, Sophia G. Liva, Christopher C. Coss, Jiang Wang, Soun Khountham, Paul Monk, Charles L. Shapiro, Richard Piekarz, Craig C. Hofmeister, D. Bradley Welling, Amir Mortazavi

Institutions: The Ohio State University, University of Utah, Huntsman Cancer Institute, Baptist MD Anderson Cancer Center, National Cancer Institute, Winship Cancer Institute, Massachusetts Eye and Ear Infirmary, Harvard University, Massachusetts General Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Language: English

Topic: Histone Deacetylase Inhibitors Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute

Awards: G1923021002, Phase I Trials of Anti-Cancer Agents, G4220058336, The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network

OpenAlex ID: W3121920478

FWCI: 1.554

Cites: 84

Cited by: 28

Related to: 10